CTRI/2024/04/065534RecruitingPhase 3
A Randomized, Open Label, Multicentric, Parallel group, Active-Controlled Comparative Phase III Trial to Evaluate the Efficacy and Safety of Upadacitinib Extended Release Tablets in Comparison with Tofacitinib Tablets in Adults with moderately to severely active ulcerative colitis - NI
M/s. MSN Laboratories Private Limited0 sites0 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1.Adult male or female subjects with age =18 years and = 65 years of age at the time of screening.
- •2.Subjects who are willing and able to sign informed consent approved by an Independent Ethics Committee and Institutional Review Board for participation in the study and willing to adhere to all protocol procedures.
- •3.Subjects with moderately to severely (as assessed by the modified Mayo score) active ulcerative colitis (confirmed endoscopically prior to baseline) who have had an inadequate response or intolerance to one or more TNF blockers.
- •4.Male or female subjects of child-bearing potential must agree to use medically acceptable forms of contraception during the study.
- •5.Subject with a negative test for Tuberculosis with Mantoux Test.
Exclusion Criteria
- •1. Subject with history of hypersensitivity to investigational products or to any of the excipient.
- •2. Participant with current diagnosis of Crohns disease or diagnosis of indeterminate colitis
- •3. Current diagnosis of fulminant colitis and or toxic megacolon
- •4. Known active bacterial, viral, fungal, mycobacterial, or other infection including tuberculosis or atypical mycobacterial disease, but excluding fungal infections of nail beds.
- •5. Total white blood cell count less than 2,500- µL, absolute neutrophil count less than 1,500-µL platelet count less than 100,000-µL absolute lymphocyte count less than 800-µL and hemoglobin less than 10 g-dL.
- •6. Renal system: estimated glomerular filtration rate eGFR less than40 mL-minute-1.73 m2.
- •7. Subject has active TB or meets TB exclusionary parameters
- •8. Receipt of any live vaccine within 4 weeks prior to the first dose of study drug, or expected need of live vaccination during study participation including at least 4 weeks after the last dose of study drug.
- •9. Subjects with medical history of Oncological Conditions since last 2 years
- •10. History of clinically significant drug or alcohol abuse within the last 6 months per Investigators judgment.
- •11. History of moderate to severe congestive heart failure New York Heart Association class III or IV
- •12. History of myocardial infarction, coronary stenting or CVA within 6 months prior to Screening.
- •13. Uncontrolled hypertension as defined by a persistent systolic blood pressure BP greater than 160 mmHg or diastolic BP greater than 100 mmHg. For subjects with known hypertension, the subjects BP must be stable for at least 4 weeks on current, stable anti-hypertensive medications.
- •14. Clinically relevant or significant ECG abnormalities, including ECG with QT interval corrected for heart rate QTc using Fridericias correction formula QTcF greater than 450 msec males or greater than 470 msec - females.
- •15. Infection requiring treatment with parenteral anti-infectives within 30 days, or oral anti-infectives within 14 days prior the first dose of study drug.
- •16. Subjects with clinically significant impaired hepatic function. SGOT & SGPT more than 3X the UNL and-or Total bilirubin more than 1.5X the UNL.
- •17. Subjects with suspected signs and symptoms of COVID-19-confirmed novel coronavirus infection or with a recent history of travel-contact with any COVID-19 positive subject-isolation-quarantine in the last 14 days
- •18. Female subjects who are pregnant or lactating or planning to become pregnant during the study period.
- •19. Females who are not ready to use acceptable contraceptive methods during the course of study.
- •20. Concurrent participation in another clinical trial or any investigational therapy within 90 days prior to signing informed consent.
- •21. Subjects with history of HIV and or Hepatitis B and or Hepatitis C.
- •22. Suspected inability or unwillingness to comply with the study procedures.
- •23. Subjects with clinically significant disorders that, in the opinion of the investigator, would result in jeopardizing subjects safety and efficacy of the drug.
- •24. Subject with a positive test for Tuberculosis with QuantiFERON-TB Gold test
Investigators
Similar Trials
Completed
Phase 3
se of Clevira in COVID19 patientsCTRI/2020/05/025483Apex Laboratories Pvt Ltd100
Completed
Not Applicable
Three Arm Clinical Study to Compare the Efficacy and Safety of Test formulations of Permethrin in adults with scabiesCTRI/2018/01/011266Glasshouse Pharmaceuticals Limited
Recruiting
Phase 3
a study to assess effectiveness amd safety of combination of two medicine will be used for treatment of gastroesophageal reflux disease.CTRI/2012/02/002406Torrent Pharmaceuticals Ltd200
Unknown
Phase 3
A Study to investigate the effect of Ticagrelor sustained release tablets in patients with the history of heart attack on a background of aspiriCTRI/2020/03/023925Synokem Pharmaceuticals Ltd
Recruiting
Phase 3
To Evaluate Efficacy and Safety of Norethisterone CR Tablet Versus Medroxyprogesterone Acetate Tablet for the treatment of Women with Dysfunctional Uterine Bleeding due to Hormonal Imbalance.CTRI/2017/02/007931Synokem Pharmaceuticals Limited188